FULCRUM THERAPEUTICS INC. - COMMON STOCK

Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET

04 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function

24 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)

21 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

12 May 2021 07:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

07 May 2021 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

06 May 2021 07:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer

06 May 2021 07:00:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8:00 a.m. ET

29 Apr 2021 07:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference

09 Apr 2021 13:15:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development

24 Mar 2021 09:29:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

18 Mar 2021 11:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

04 Mar 2021 07:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces CEO Transition

04 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET

26 Feb 2021 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Recognizes Rare Disease Day 2021

26 Feb 2021 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

19 Feb 2021 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

22 Jan 2021 16:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock

19 Jan 2021 22:34:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

19 Jan 2021 16:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer

19 Jan 2021 16:00:00 By Nasdaq GlobeNewswire